Patton Fund Management Inc. Raises Stock Position in McKesson Corporation $MCK

Key Points

• Patton Fund Management raised its stake in McKesson by 64.3% in Q4 to 7,354 shares, holdings now valued at about $6.03 million.
• McKesson beat Q results (EPS $9.34 vs. $9.19 est.; revenue $106.16B, +11.4% YoY) and issued aggressive FY2026 guidance of $38.80–$39.20 EPS.
• Analysts maintain a consensus of "Moderate Buy" with a mean target price of about $970.93 (13 Buys, 3 Holds).

Patton Fund Management Inc. boosted its holdings in McKesson Corporation (NYSE:MCK - Free Report) by 64.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 7,354 shares of the company's stock after buying an additional 2,878 shares during the period. Patton Fund Management Inc.'s holdings in McKesson were worth $6,032,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in MCK. Brighton Jones LLC boosted its holdings in shares of McKesson by 46.3% during the 4th quarter. Brighton Jones LLC now owns 2,523 shares of the company's stock valued at $1,438,000 after purchasing an additional 798 shares during the last quarter. Caxton Associates LLP bought a new position in shares of McKesson during the 1st quarter valued at about $233,000. Sivia Capital Partners LLC boosted its holdings in shares of McKesson by 77.9% during the 2nd quarter. Sivia Capital Partners LLC now owns 685 shares of the company's stock valued at $502,000 after purchasing an additional 300 shares during the last quarter. Treasurer of the State of North Carolina boosted its holdings in shares of McKesson by 0.9% during the 2nd quarter. Treasurer of the State of North Carolina now owns 58,623 shares of the company's stock valued at $42,958,000 after purchasing an additional 508 shares during the last quarter. Finally, Osterweis Capital Management Inc. bought a new position in shares of McKesson during the 2nd quarter valued at about $166,000. Institutional investors own 85.07% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on MCK. Bank of America dropped their price objective on shares of McKesson from $1,040.00 to $1,000.00 and set a "buy" rating for the company in a report on Monday, April 6th. Raymond James Financial set a $970.00 price objective on shares of McKesson in a report on Thursday, March 5th. Leerink Partners reaffirmed an "outperform" rating and issued a $1,085.00 price target on shares of McKesson in a report on Thursday, March 5th. Evercore reaffirmed an "outperform" rating on shares of McKesson in a report on Thursday, March 5th. Finally, Mizuho increased their price target on shares of McKesson from $880.00 to $885.00 and gave the company a "neutral" rating in a report on Thursday, February 5th. Thirteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $970.93.

McKesson Stock Performance

Shares of NYSE:MCK opened at $863.51 on Tuesday. The firm has a market cap of $105.77 billion, a PE ratio of 24.84, a price-to-earnings-growth ratio of 1.25 and a beta of 0.42. The firm's 50 day simple moving average is $916.57 and its 200-day simple moving average is $852.76. McKesson Corporation has a one year low of $637.00 and a one year high of $999.00.

McKesson (NYSE:MCK - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping analysts' consensus estimates of $9.19 by $0.15. The business had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company's quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the company posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Equities research analysts predict that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd were issued a $0.82 dividend. The ex-dividend date of this dividend was Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson's payout ratio is presently 9.43%.

Insider Activity

In other McKesson news, Director Maria Martinez sold 349 shares of McKesson stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total value of $328,014.63. Following the completion of the transaction, the director owned 301 shares of the company's stock, valued at approximately $282,900.87. The trade was a 53.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michele Lau sold 2,725 shares of the business's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the sale, the executive vice president directly owned 3,247 shares of the company's stock, valued at $3,214,530. This represents a 45.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,592 shares of company stock worth $3,518,555 over the last three months. Corporate insiders own 0.08% of the company's stock.

About McKesson

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.